July 27, 2011

Metabolix and CJ CheilJedang Announce Joint Development Agreement for Commercialization of Renewable C4 Chemicals

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Metabolix, Inc. (NASDAQ: MBLX) and CJ CheilJedang (CJ) announced today the execution of a joint development agreement to advance production technology and assess investment options for the commercialization of renewable C4 chemicals via fermentation. The C4 chemical market is a $3 billion industry growing at 4 percent per year. C4 chemical products are used in a wide range of applications including engineering plastics, fabrics and fibers, personal care products and in semiconductor manufacturing.

Within the joint development agreement, CJ will contribute fermentation assets and expertise to produce pilot quantities of dried whole fermentation broth containing raw C4 chemicals. Metabolix will continue the development of microbial strains and the scale-up of its proprietary FASTTM recovery process to produce high-purity C4 chemicals. The FASTTM recovery process is a low-cost, energy-efficient approach to recover high-purity renewable chemicals directly from dried whole fermentation broth. In addition, Metabolix and CJ will collaborate closely to develop a detailed market and economic analysis examining all aspects of an investment to commercialize renewable C4 chemicals. The initial market entry is expected to be through gamma butyrolactone (GBL), with subsequent growth into butanediol (BDO), tetrahydrofuran (THF) and polyester engineering resins (PBT).

"We are excited to be working with a company with such a strong track record of growth," noted Rick Eno, president and CEO of Metabolix. "CJ's global fermentation asset base and product expansion plans fit very well with the market needs for C4 chemicals. Together, we hope to meet the strong market demand for this important family of materials."

CJ BIO, a division of CJ CheilJedang, is a world leader in bio fermentation based R&D and manufacturing with a range of amino acids, including lysine, as well as nucleotides. CJ BIO operates world-scale fermentation facilities in China, Indonesia and Brazil; these sites, as well as new potential sites, will be analyzed as production bases for renewable C4 chemicals based on the Metabolix technology.

John Kang, VP of CJ BIO, noted, "As CJ continues to execute its bio-products growth strategy, we see the addition of renewable C4 chemicals as an important component. We have been impressed with the Metabolix technology and look forward to the joint development of C4 chemicals and potential collaboration in commercialization."

About Metabolix

Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience company focused on providing sustainable solutions for the world's needs for plastics, chemicals and energy. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is now developing and commercializing Mirel™, a family of high performance bioplastics, which are biobased and biodegradable alternatives to many petroleum-based plastics, through Telles, a joint venture between Metabolix and Archer Daniels Midland Company. Metabolix is also developing biosourced industrial chemicals and a proprietary platform technology for co-producing plastics, chemicals and energy from crops such as switchgrass, oilseeds and sugarcane. For more information, please visit http://www.metabolix.com. (MBLX-G)

About CJ CheilJedang

CJ CheilJedang, a Korean-based food, feed, and bioscience company, is a global leader in the area of industrial biotechnology with innovations in fermentation and purification technologies. CJ is a leading producer of fermentation-based products such as feed amino acids, MSG, and Nucleotides with global manufacturing and business operations in 6 continents. As a socially responsible company, CJ strives toward practicing carbon-neutral manufacturing operations by utilizing renewable raw materials and developing value-added co-products to minimize waste into the environment.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expectations for Metabolix research and development, including the joint development collaboration, and plans for commercialization of renewable C4 chemicals, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Schwartz Communications
Keith Giannini or Jen Barlow, 781-684-0770
James Palczynski, 203-682-8229

Source: Metabolix, Inc.

News Provided by Acquire Media

Close window | Back to top

Copyright 2017 Yield10 Bioscience, Inc.